HDS named Concur App Center “Partner of the Year”
IRVINE, Calif. — Healthcare Data Solutions on Thursday announced that they were named Concur App Center “Partner of the Year” for the second consecutive year. In 2012, HDS and Concur, a provider of spend management services, formed a partnership to deliver real-time access to HDS for Concur expense clients. The resulting cloud-based application, HDSverify for Concur Connect, allows Concur users to locate and verify healthcare provider information for spend tracking and Sunshine Act reporting.
In an effort to increase transparency of the financial interactions between physicians and healthcare vendors, the Open Payments/Physician Payments Sunshine Act requires manufacturers of drugs, medical devices and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value given to physicians and teaching hospitals. Healthcare Data Solutions’ Concur Connect service enables users to perform expense report searches for NPI, taxonomy, state license and address data in real time.
“Healthcare Data Solutions has demonstrated an exceptional commitment to our partnership, delivering a critical app that enables Sunshine Act compliance and spend reporting for our clients across health systems, life sciences and hospitals,” stated Jigish Avalani, SVP and general manager of Platform Services at Concur. “We are pleased to recognize and award HDS for their outstanding achievements and dedication to serving our client’s compliance needs.”
NYT: Inversion becoming a hot topic among Fortune 500 companies
NEW YORK — With Pfizer’s targeted takeover of AstraZeneca, there’s been much talk about inversion, or the practice of re-domiciling a company’s headquarters to another country in an effort to save on corporate taxes. It’s a hot topic among Fortune 500 companies, The New York Times noted earlier this week, reporting that at least 17 companies have reached out to their banks to explore possible inversion-inspired acquisitions.
The talk has extended to the Walgreens/Alliance Boots deal — beginning in February 2015 Walgreens will have six months to decide whether or not to acquire Alliance Boots outright — though Walgreens has not given any indication that it’s considering an inversion.
During the company’s last conference call on March 25, president and CEO Greg Wasson suggested that a Walgreens inversion was not up for consideration. "We have no plans to … do an inversion or re-domicile the company," he told analysts. "What we are focused on frankly is [making] sure that we put our board and our shareholders into position to make the right decision on step two."
"We regularly meet with our investors and always welcome their input," Walgreens spokesman Michael Polzin shared with DSN. "Over the past year, we have made significant progress in our strategic partnership with Alliance Boots as we move toward the window for exercising the second step of our transaction. Our focus is always on analyzing and doing what is in the best long-term interest of our company and its shareholders, and when we have something more definitive to announce about our future structure and strategies, we will do so."
Greenstone launches rifabutin capsules
PEAPACK, N.J. — Greenstone, a U.S.-based generic pharmaceutical subsidiary of Pfizer, announced the introduction of rifabutin capsules to its product line. The capsules are offered in the dosage strength of 150-mg x 100.
The drug is the authorized generic version of Mycobutin and is used for the prevention of disseminated mycobacterium avium complex disease in patients with advanced HIV infection.